Literature DB >> 1304706

Human onchocerciasis in the lower Jos Plateau, central Nigeria: the prevalence, geographical distribution and epidemiology in Akwanga and Lafia local government areas.

G O Ufomadu1, A U Akpa, I M Ekejindu.   

Abstract

An investigation of human infection with Onchocerca volvulus and the resulting clinical disease was carried out for the Nigerian National Onchocerciasis Control Programme between July and August 1989 [corrected]. The survey covered 10.6% of the rural population in 41 savanna villages of central Nigeria. Of the 8451 self-selected individuals examined, 900 (10.6%) had skin microfilariae (Mf). There were differences between villages in both endemicity and intensity of infection, but in general the number of both Mf carriers and cases of clinical onchocerciasis increased with age. The disease in the Mf carriers showed as blindness (0.8%), onchocercal nodules (0.6%), leopard skin (1.6%) and pruritus (2.8%). Of 35 persons with lymphatic complications, 19 had hanging groin, 10 had elephantiasis and six had hydrocoele. Onchocerciasis was mesoendemic in the rocky northern escarpments, and became hypoendemic and sporadic in the southern uplands of sedimentary geological origin.

Entities:  

Mesh:

Year:  1992        PMID: 1304706     DOI: 10.1080/00034983.1992.11812720

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  2 in total

1.  CD4(+), CD8(+), immunoglobulin status and ocular lesions among some onchocerciasis-infected rural Nigerians.

Authors:  O P G Nmorsi; N C D Ukwandu; O J Alabi-Eric; W Popoola; M Osita-Emina
Journal:  Parasitol Res       Date:  2007-01-06       Impact factor: 2.289

2.  The geographic distribution of onchocerciasis in the 20 participating countries of the African Programme for Onchocerciasis Control: (1) priority areas for ivermectin treatment.

Authors:  Mounkaila Noma; Honorat G M Zouré; Afework H Tekle; Peter A I Enyong; Bertram E B Nwoke; Jan H F Remme
Journal:  Parasit Vectors       Date:  2014-07-22       Impact factor: 3.876

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.